Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis

Current Treatment Options in Oncology

Volumn 17, Issue 2, 2016, Pages 1-9

  Brahmi, Mehdi ^a   Vinceneux, Armelle ^a,b   Cassier, Philippe A ^a  

^a CENTRE LÉON BÉRARD   (France)

^b CHU BRETONNEAU   (France)

Author keywords

Anti TNF alpha; Colony stimulating factor 1; Colony stimulating factor 1 receptor; Emactuzumab; Imatinib; Nilotinib; Pigmented villonodular synovitis; PLX3397; Systemic therapy; Tenosynovial giant cell tumor

Indexed keywords

COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; EMACTUZUMAB; ETANERCEPT; FPA 008; IMATINIB; INFLIXIMAB; MONOCLONAL ANTIBODY; NILOTINIB; PLX 3397; PROTEIN CSF1R; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; YTTRIUM 90; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CANCER THERAPY; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; JOINT TUMOR; PATHOGENESIS; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PIGMENTED VILLONODULAR SYNOVITIS; PROGNOSIS; PROTEIN TARGETING; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SURGICAL APPROACH; SYNOVECTOMY; TENOSYNOVIAL GIANT CELL TUMOR; TREATMENT INDICATION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; GIANT CELL TUMORS; SYNOVITIS, PIGMENTED VILLONODULAR;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; GIANT CELL TUMORS; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SYNOVITIS, PIGMENTED VILLONODULAR;

EID: 84961325711     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-015-0385-x     Document Type: Review

References (41)

1. Martin RC, Osborne DL, Edwards MJ, Wrightson W, McMasters KM. Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence. Oncol Rep. 2000;7:413–9.
2. Mendenhall WM, Mendenhall CM, Reith JD, Scarborough MT, Gibbs CP, Mendenhall NP. Pigmented villonodular synovitis. Am J Clin Oncol. 2006;29:548–50. doi:10.1097/01.coc.0000239142.48188.f6.
3. Sirlyn Q. Pigmented villonodular synovitis. Sonography. 2014;1:19–24. doi:10.1002/sono.12003.
4. Posligua L, McDonald DJ, Dehner LP. Diffuse-type tenosynovial giant cell tumor in association with neurofibromatosis type 1-Noonan syndrome: possibly more than a chance relationship. Am J Surg Pathol. 2006;30:734–8.
5. Abdul-Karim FW, el-Naggar AK, Joyce MJ, Makley JT, Carter JR. Diffuse and localized tenosynovial giant cell tumor and pigmented villonodular synovitis: a clinicopathologic and flow cytometric DNA analysis. Hum Pathol. 1992;23:729–35.
6. WHO. Classification of tumours of soft tissue and bone. 4th ed. Lyon: World Health Organization; 2013.
7. Yoon H-J, Cho Y-A, Lee J-I, Hong S-P, Hong S-D. Malignant pigmented villonodular synovitis of the temporomandibular joint with lung metastasis: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111:e30–6. doi:10.1016/j.tripleo.2010.11.031.
8. Righi A, Gambarotti M, Sbaraglia M, Frisoni T, Donati D, Vanel D, et al. Metastasizing tenosynovial giant cell tumour, diffuse type/pigmented villonodular synovitis. Clin Sarcoma Res. 2015;5:15. doi:10.1186/s13569-015-0030-2.
9. Xie G, Jiang N, Liang C, Zeng J, Chen Z, Xu Q, et al. Pigmented villonodular synovitis: a retrospective multicenter study of 237 cases. PLoS One. 2015;10:e0121451. doi:10.1371/journal.pone.0121451.
10. Verspoor FGM, Zee AAG, Hannink G, van der Geest ICM, Veth RPH, Schreuder HWB. Long-term follow-up results of primary and recurrent pigmented villonodular synovitis. Rheumatol Oxf Engl. 2014;53:2063–70. doi:10.1093/rheumatology/keu230.
11. Cheng XG, You YH, Liu W, Zhao T, Qu H. MRI features of pigmented villonodular synovitis (PVNS). Clin Rheumatol. 2004;23:31–4. doi:10.1007/s10067-003-0827-x.
12. Dodd LG, Major NM. Fine-needle aspiration cytology of articular and periarticular lesions. Cancer. 2002;96:157–65. doi:10.1002/cncr.10615.
13. West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006;103:690–5. doi:10.1073/pnas.0507321103. CSF1 overexpression by these cells.
14. Cupp JS, Miller MA, Montgomery KD, Nielsen TO, O'Connell JX, Huntsman D, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007;31:970–6. doi:10.1097/PAS.0b013e31802b86f8.
15. Macrophages—advances in research and application: 2012 Edition. ScholarlyEditions. 2012.
16. Ogilvie-Harris DJ, Weisleder L. Arthroscopic synovectomy of the knee: is it helpful? Arthrosc J Arthrosc Relat Surg. 1995;11:91–5. doi:10.1016/0749-8063(95)90094-2.
17. de Visser E, Veth RPH, Pruszczynski M, Wobbes T, de Putte LBAV. Diffuse and localized pigmented villonodular synovitis: evaluation of treatment of 38 patients. Arch Orthop Trauma Surg. 1999;119:401–4. doi:10.1007/s004020050009.
18. Palmerini E, Staals EL, Maki RG, Pengo S, Cioffi A, Gambarotti M, et al. Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. Eur J Cancer Oxf Engl 1990. 2015;51:210–7. doi:10.1016/j.ejca.2014.11.001.
19. Kotwal PP, Gupta V, Malhotra R. Giant-cell tumour of the tendon sheath is radiotherapy indicated to prevent recurrence after surgery? J Bone Joint Surg (Br). 2000;82-B:571–3.
20. Ottaviani S, Ayral X, Dougados M, Gossec L. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arthritis Rheum. 2011;40:539–46. doi:10.1016/j.semarthrit.2010.07.005.
21. Wiss DA. Recurrent villonodular synovitis of the knee. Successful treatment with yttrium-90. Clin Orthop. 1982;169:139–44.
22. Shabat S, Kollender Y, Merimsky O, Isakov J, Flusser G, Nyska M, et al. The use of surgery and yttrium 90 in the management of extensive and diffuse pigmented villonodular synovitis of large joints. Rheumatol Oxf Engl. 2002;41:1113–8.
23. Bickels J, Isaakov J, Kollender Y, Meller I. Unacceptable complications following intra-articular injection of yttrium 90 in the ankle joint for diffuse pigmented villonodular synovitis. J Bone Joint Surg Am. 2008;90:326–8. doi:10.2106/JBJS.G.00441.
24. Heyd R, Seegenschmiedt MH, Micke O. The role of external beam radiation therapy in the adjuvant treatment of pigmented villonodular synovitis. Z Für Orthop Unfall. 2011;149:677–82. doi:10.1055/s-0030-1250687.
25. Yoshida W, Uzuki M, Kurose A, Yoshida M, Nishida J, Shimamura T, et al. Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis. Hum Pathol. 2003;34:65–73. doi:10.1053/hupa.2003.52.
26. O’Keefe RJ, Rosier RN, Teot LA, Stewart JM, Hicks DG. Cytokine and matrix metalloproteinase expression in pigmented villonodular synovitis may mediate bone and cartilage destruction. Iowa Orthop J. 1998;18:26–34.
27. Kroot E, Kraan M, Smeets T, Maas M, Tak P, Wouters J. Tumour necrosis factor α blockade in treatment resistant pigmented villonodular synovitis. Ann Rheum Dis. 2005;64:497–9. doi:10.1136/ard.2004.025692.
28. Fiocco U, Sfriso P, Oliviero F, Sovran F, Scagliori E, Pagnin E, et al. Intra-articular treatment with the TNF-alpha antagonist, etanercept, in severe diffuse pigmented villonodular synovitis of the knee. Reumatismo. 2006;58:268–74.
29. Dewar AL, Cambareri AC, Zannettino ACW, Miller BL, Doherty KV, Hughes TP, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005;105:3127–32. doi:10.1182/blood-2004-10-3967.
30. Taylor JR, Brownlow N, Domin J, Dibb NJ. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene. 2006;25:147–51. doi:10.1038/sj.onc.1209007.
31. Blay J-Y, El Sayadi H, Thiesse P, Garret J, Ray-Coquard I. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol Off J Eur Soc Med Oncol ESMO. 2008;19:821–2. doi:10.1093/annonc/mdn033. This single patient report is the first proof of concept for therapeutically targeting the CSF1/CSF1R axis in patients with advanced TGCT/PVNS.
32. Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2012;118:1649–55. doi:10.1002/cncr.26409.
33. Stacchiotti S, Crippa F, Messina A, Pilotti S, Gronchi A, Blay JY, et al. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. Clin Sarcoma Res. 2013;3:8. doi:10.1186/2045-3329-3-8.
34. Brownlow N, Russell AE, Saravanapavan H, Wiesmann M, Murray JM, Manley PW, et al. Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia. 2008;22:649–52. doi:10.1038/sj.leu.2404944.
35. Gelderblom H, Pérol D, Chevreau C, Tattersall MNH, Stacchiotti S, Casali PG, et al. An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment. J Clin Oncol. Available: http://meetinglibrary.asco.org/content/98976-114.
36. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25:846–59. doi:10.1016/j.ccr.2014.05.016.
37. Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16:949–56. doi:10.1016/S1470-2045(15)00132-1. Report on the efficacy of newer, more specific CSF1R inhibitors in TGCT, confirming the major role of this pathway in this rare disease.
38. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373:428–37. doi:10.1056/NEJMoa1411366. Report on the efficacy of newer, more specific CSF1R inhibitors in TGCT, confirming the major role of this pathway in this rare disease.
39. Sikaria S, Heim-Hall J, Diaz EH, Williams R, Sankhala K, Laabs B, et al. Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor. Target Oncol. 2014;9:73–9. doi:10.1007/s11523-013-0267-8.
40. Cassier PA, Maki RG, Wagner AJ, Bompas E, Gelderblom H, Kroep JR, et al. Imatinib mesylate (IM) activity in patients (pts) with locally advanced tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT). ASCO Meet Abstr. 2015;33:10561.
41. Nissen MJ, Boucher A, Brulhart L, Menetrey J, Gabay C. Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumour. Ann Rheum Dis. 2014;73:947–8. doi:10.1136/annrheumdis-2013-204589.